Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MicroPort CardioFlow Medtech's revenue for the
six
months ended in Dec. 2025 was $25.10 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $57.04 Mil.
MicroPort CardioFlow Medtech's Revenue per Share for the
six
months ended in Dec. 2025 was $0.05.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.12.
Warning Sign:
MicroPort CardioFlow Medtech Corp revenue growth has slowed down over the past 12 months.
During the past 8 years, MicroPort CardioFlow Medtech's highest 3-Year average Revenue per Share Growth Rate was 127.30% per year. The lowest was 14.60% per year. And the median was 30.65% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
MicroPort CardioFlow Medtech Revenue Related Terms
MicroPort CardioFlow Medtech Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, MicroPort CardioFlow Medtech's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MicroPort CardioFlow Medtech Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MicroPort CardioFlow Medtech's Revenue distribution charts can be found below:
* The bar in red indicates where MicroPort CardioFlow Medtech's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $57.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MicroPort CardioFlow Medtech (MROPF) has a Revenue of $57.04 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on MicroPort CardioFlow Medtech and its competitors.
Is MicroPort CardioFlow Medtech's Revenue too high?
MicroPort CardioFlow Medtech's current Revenue is $57.04 Mil. Overall, MicroPort CardioFlow Medtech has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does MicroPort CardioFlow Medtech's Revenue compare to ABT and SYK?
MicroPort CardioFlow Medtech's Revenue of $57.04 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on MicroPort CardioFlow Medtech and its competitors. MicroPort CardioFlow Medtech's current Revenue is $57.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MicroPort CardioFlow Medtech stock overvalued right now?
MicroPort CardioFlow Medtech (MROPF) has a current Revenue of $57.04 Mil. The stock's GF Value™ is $3.23, compared to a current price of $0.65 — trading 80% below its estimated fair value. The current Revenue is $57.04 Mil. MicroPort CardioFlow Medtech's overall GF Score™ is 59/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For MicroPort CardioFlow Medtech (MROPF), the current Revenue is $57.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MicroPort CardioFlow Medtech (MROPF) Overvalued in 2026?
Based on GuruFocus' analysis, MicroPort CardioFlow Medtech stock appears to be undervalued.
The current stock price of $0.65 is trading 80% below its estimated GF Value™ of $3.23.
Key valuation signals for MROPF:
Revenue: $57.04 Mil
GF Value™: $3.23 vs. price of $0.65 (80% below fair value)
No single metric tells the full story. See the MROPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MicroPort CardioFlow Medtech Corp is a medical device company in China focusing on the research, development, and commercialization of transcatheter and surgical solutions for valvular heart diseases. The company's product portfolio consists of VitaFlow, VitaFlow Liberty, Angelguide and AnchorMan. The Group derives revenue from the sales of medical devices through appointed distributors. It derives maximum revenue from PRC.
59GF Score
Get the complete analysis for MROPF
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MROPF has been successfully added to your 
